Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 187

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

PI3K/AKT/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer

Open access
Zhang, Huan-ping, Jiang, Rui-yuan, Zhu, Jia-yu, Sun, Ke-na, Huang, Yuan, Zhou, Huan-huan, Zheng, Ya-bing, Wang, Xiao-jia · 2024 · Breast Cancer

Abstract

Triple-negative breast cancer (TNBC) is a highly heterogeneous tumor lacking estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. It has higher aggressiveness and metastasis than other subtypes, with limited effective therapeutic strategies, leading to a poor prognosis. The phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mechanistic target of rapamycin (mTOR) signaling pathway is prevalently over-activated in human cancers and contributes to breast cancer (BC) growth, survival, proliferation, and angiogenesis, which could be an interesting therapeutic target. This review summarizes the PI3K/AKT/mTOR signaling pathway activation mechanism in TNBC and discusses the relationship between its activation and various TNBC subtypes. We also report the latest clinical studies on kinase inhibitors related to this pathway for treating TNBC. Our review discusses the issues that need to be addressed in the clinical application of these inhibitors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s12282-024-01567-5

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 187

Metadata

Authors
Zhang, H.-P., Jiang, R.-Y., Zhu, J.-Y., Sun, K.-N., Huang, Y., Zhou, H.-H., Zheng, Y.-B., & Wang, X.-J.
Venue
Breast Cancer
Published
2024-04-17
Volume
31
Issue
4
Pages
539-551
ISSN
  • 1340-6868 (ISSN-L)
  • 1880-4233
OpenAlex
W4394872839
Cited by
187
References
7
FWCI
21.73
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PI3K/AKT/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer. https://app.cochat.ai/papers/10.1007/s12282-024-01567-5
The paper
Zhang, H.-P., Jiang, R.-Y., Zhu, J.-Y., Sun, K.-N., Huang, Y., Zhou, H.-H., Zheng, Y.-B., & Wang, X.-J. (2024). PI3K/AKT/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer. Breast Cancer. https://doi.org/10.1007/s12282-024-01567-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.